We’ve dedicated this page to keeping you up to date on the latest SCN2A news and studies. Here you’ll be able to explore our latest articles, contribute to community posts, read other people’s stories, and much more.
Praxis and The Florey Institute Collaborate on Innovative SCN2A Research
Exciting news for the SCN2A community! Praxis has recently entered into an innovative research collaboration with The Florey Institute of Neuroscience and Mental Health.
This collaboration will focus on developing three novel ASOs, including a lead program for the treatment of SCN2A loss-of-function mutations, the foremost cause of genetically associated autism, and two additional rare epilepsy targets.
Through this partnership, Praxis will now have research initiatives for SCN2A gain-of-function and loss-of-function mutations in development. Finding therapies that treat this complex condition and getting them to pediatric patients faster is critical to improving the lives of these children and their families sooner.
At Praxis, we are passionate about science. But we are equally passionate about the people that science may help. Only by working together can we achieve our goal of finding new treatments for SCN2A-related disorders. We invite you to reach out to us at firstname.lastname@example.org with additional questions or thoughts.